2 research outputs found
Synthesis of Verubecestat, a BACE1 Inhibitor for the Treatment of Alzheimer’s Disease
Verubecestat is an inhibitor of β-secretase
being evaluated
for the treatment of Alzheimer’s disease. The first-generation
route relies on an amide coupling with a functionalized aniline, the
preparation of which introduces synthetic inefficiencies. The second-generation
route replaces this with a copper-catalyzed C–N coupling, allowing
for more direct access to the target. Other features of the new route
include a diastereoselective Mannich-type addition into an Ellman
sulfinyl ketimine and a late-stage guanidinylation
Efficient, Chemoenzymatic Process for Manufacture of the Boceprevir Bicyclic [3.1.0]Proline Intermediate Based on Amine Oxidase-Catalyzed Desymmetrization
The key structural feature in Boceprevir, Merck’s
new drug
treatment for hepatitis C, is the bicyclic [3.1.0]Âproline moiety “P2”.
During the discovery and development stages, the P2 fragment was produced
by a classical resolution approach. As the drug candidate advanced
through clinical trials and approached regulatory approval and commercialization,
Codexis and Schering–Plough (now Merck) jointly developed a
chemoenzymatic asymmetric synthesis of P2 where the net reaction was
an oxidative Strecker reaction. The key part of this reaction sequence
is an enzymatic oxidative desymmetrization of the prochiral amine
substrate